79e77cb6-d567-4e9b-99df-e38e6e05d72e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.500
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- MYC_TARGETS_V2+0.300
- ADIPOGENESIS+0.200
- BILE_ACID_METABOLISM+0.200
- COAGULATION+0.200
- DNA_REPAIR+0.200
- FATTY_ACID_METABOLISM+0.200
- MYC_TARGETS_V1+0.200
- PEROXISOME+0.200
Top 10 suppressed
- ANDROGEN_RESPONSE-0.400
- ANGIOGENESIS-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- G2M_CHECKPOINT-0.300
- INFLAMMATORY_RESPONSE-0.300
- KRAS_SIGNALING_UP-0.300
- MITOTIC_SPINDLE-0.300
- NOTCH_SIGNALING-0.300
- TGF_BETA_SIGNALING-0.300
- UV_RESPONSE_DN-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GU-A763-01A-11R-A32O-07 | — | — | 0.863 |
| 2 | TCGA-A2-A3XV-01A-21R-A239-07 | — | B | 0.835 |
| 3 | TCGA-MT-A67A-01A-11R-A30B-07 | — | — | 0.835 |
| 4 | SRR1313092 | — | B | 0.812 |
| 5 | fa9f3cc6-06eb-4cfd-8f85-9d13df39d11e | — | — | 0.807 |
| 6 | TCGA-LL-A5YM-01A-11R-A28M-07 | — | B | 0.791 |
| 7 | MDT-AP-1302 | Med | Medulloblastoma | 0.781 |
| 8 | MNG908 | — | — | 0.780 |
| 9 | 20140057.LumB | — | B | 0.775 |
| 10 | TCGA-AC-A3YJ-01A-11R-A22U-07 | — | B | 0.775 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |